타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | zolbetuximab (Vyloy, IMAB362, zolbetuximab-clzb, claudiximab) Astellas·CLDN18.2 (claudin-18.2) 26 trials |
|---|---|
Overview Program | Vyloy (zolbetuximab) |
Overview Company | Astellas |
Overview Modality | ANTIBODY |
Overview Target | CLDN18.2 (claudin-18.2) |
Overview Indication | CLDN18.2-positive HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Exploits a tight-junction protein that only becomes accessible after malignant transformation, creating tumor selectivity without a novel modality. |
Positioning Known limitation | CLDN18.2 heterogeneity and loss under treatment pressure. |
Positioning Development positioning | 1L with fluoropyrimidine and platinum chemotherapy |
MoA Mechanism | Binds CLDN18.2 on gastric tumor cells and kills them through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. |
MoA Biomarker | CLDN18.2 IHC with ≥75% of tumor cells at moderate-to-strong membranous staining. |
Toxicology Major finding | Nausea and vomiting are frequent and often infusion-related, requiring rate adjustment and antiemetics. Hypoalbuminemia, appetite loss, and hypersensitivity also occur. |
Toxicology CRS | N/A |
Clinical Safety signal | Nausea and vomiting are frequent and often infusion-related, requiring rate adjustment and antiemetics. Hypoalbuminemia, appetite loss, and hypersensitivity also occur. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | zolbetuximab (Vyloy, IMAB362, zolbetuximab-clzb, claudiximab) Astellas·CLDN18.2 (claudin-18.2) 26 trials |
|---|---|
Overview Program | Vyloy (zolbetuximab) |
Overview Company | Astellas |
Overview Modality | ANTIBODY |
Overview Target | CLDN18.2 (claudin-18.2) |
Overview Indication | CLDN18.2-positive HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Exploits a tight-junction protein that only becomes accessible after malignant transformation, creating tumor selectivity without a novel modality. |
Positioning Known limitation | CLDN18.2 heterogeneity and loss under treatment pressure. |
Positioning Development positioning | 1L with fluoropyrimidine and platinum chemotherapy |
MoA Mechanism | Binds CLDN18.2 on gastric tumor cells and kills them through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. |
MoA Biomarker | CLDN18.2 IHC with ≥75% of tumor cells at moderate-to-strong membranous staining. |
Toxicology Major finding | Nausea and vomiting are frequent and often infusion-related, requiring rate adjustment and antiemetics. Hypoalbuminemia, appetite loss, and hypersensitivity also occur. |
Toxicology CRS | N/A |
Clinical Safety signal | Nausea and vomiting are frequent and often infusion-related, requiring rate adjustment and antiemetics. Hypoalbuminemia, appetite loss, and hypersensitivity also occur. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
추천 비교
추천 비교